How long does Sculptra last?

Longer than hyaluronic acid filler. The 2024 systematic review found improvements in facial lipoatrophy sustained for at least 25 months, with increased dermal thickness. That durability is the main argument for it, and it cuts both ways — a result you dislike lasts just as long.

How likely are nodules?

This is the honest weak point, because the two reviews do not agree. A 2024 systematic review of 11 trials reports nodule rates across studies of 6% to 41%. A 2026 scoping review of 40 studies puts incidence at 1.2% to 14%, and explains the spread: early studies used low dilution volumes of 2–3 mL and had much higher rates, while 8–10 mL per vial brings it to roughly 1.3–4%.

What makes nodules more likely?

Dilution volume above all — the scoping review states that higher quantities of diluent correlate with fewer nodules, and that facial treatment typically uses about 8–10 mL per vial. Injection depth and site also matter, with the periorbital region, temples and nasolabial folds named as higher risk. This is a technique-dependent treatment.

When would a nodule appear?

Two patterns. Early, at 4 to 8 weeks, from particle aggregation. Or delayed, after six months, most commonly between 9 and 14 months, and occasionally beyond two years. So a smooth result at three months is not proof you are past it.

Can Sculptra be dissolved?

No. Hyaluronidase dissolves hyaluronic acid and has no effect on poly-L-lactic acid. The scoping review's own conclusion is that prevention through adequate dilution and correct technique is the most evidence-supported approach — because management after the fact is harder.

Sculptra or ordinary filler?

They answer different questions. Filler places volume where it is injected, works immediately, and can be dissolved. Sculptra provokes a diffuse collagen response over months, lasts far longer, and cannot be undone. For a defined hollow, filler. For general facial volume loss over a broad area, this is the category — accepting that you are committing.

Treatments · also called 스컬트라, PLLA, poly-L-lactic acid

Sculptra: long-lasting volume, and the nodule question

Poly-L-lactic acid builds volume over months and lasts years. Published nodule rates run from 1.2% to 41%, and dilution volume is what moves them.

Author: Aesthetics Korea Editorial Team
Medical review: Reviewed by 2 doctorsSee methodology
Published: 8 September 2026
Last updated: 8 September 2026
Last reviewed: —5 min read

Short answer

Sculptra is injectable poly-L-lactic acid, which provokes your own collagen over months rather than filling space on the day. The reported durability is genuinely long — at least 25 months in the pooled studies — but the evidence behind that is rated low quality, and nodules are the complication to understand. Published rates run from 1.2% to 41%, and the single variable that moves them most is how much the product was diluted.

Key facts

What it is: Poly-L-lactic acid (PLLA) microparticles, reconstituted and injected as a suspension
How it works: Provokes collagen formation over months; it does not fill on the day
Duration: Effects sustained for at least 25 months in the pooled studies
Evidence quality: 11 randomised trials, around 1,169 participants — rated low quality by the reviewers
Nodules: 1.2–14% in one review and 6–41% in another; higher dilution is associated with lower rates
Reversibility: None. There is no dissolving agent, so a poor result is waited out

What it is, and what it is not

Poly-L-lactic acid microparticles, reconstituted with sterile water into a suspension and injected. Over the following months the particles are broken down and the tissue lays down collagen in response.

So it is a collagen stimulator, not a filler. Nothing is being placed to occupy a space. On the day of treatment you may look slightly fuller from the injected fluid, and that is not the result — it goes, and the real change arrives over three to six months.

Two consequences follow, and they are the reason to read the rest of this page:

You cannot judge it early.
You cannot undo it.

What the evidence shows

A 2024 systematic review in Polymers pooled 11 randomised trials covering roughly 1,169 participants.

Four studies found increased dermal thickness and significant improvement in facial lipoatrophy, with effects sustained for at least 25 months. Two found PLLA superior to injectable human collagen; three found it better than polyacrylamide hydrogel on lipoatrophy severity, skin quality, elasticity and satisfaction.

Then the reviewers' own verdict, which is the sentence to carry: PLLA is "a highly effective and long-lasting treatment for facial aesthetics with a reasonable safety profile. However, all findings are supported by low-quality evidence." Five of the eleven studies carried a high risk of bias.

Long-lasting and well liked. Not well proven.

The nodule question, and why the numbers disagree

Nodules are the complication that defines this treatment, and the published rates are wildly inconsistent — which is itself the finding.

The 2024 systematic review reports nodule rates across studies of 6% to 41%.
A 2026 scoping review of 40 studies puts incidence at 1.2% to 14%.

The second review explains the gap, and the explanation is useful: dilution volume. Early practice reconstituted a vial in 2–3 mL, and those studies had much higher nodule rates. At 8–10 mL or more per vial — now typical for facial treatment — the rate falls to roughly 1.3–4%.

Two more details worth having before a consultation:

Timing. Nodules appear in two patterns — early at 4–8 weeks from particle aggregation, or delayed beyond six months, most commonly at 9–14 months and sometimes past two years. A good result at three months does not mean you are clear.

Site. The scoping review names the periorbital region, temples and nasolabial folds as higher risk, requiring careful technique.

Nothing dissolves it

Hyaluronidase breaks down hyaluronic acid. It does nothing to poly-L-lactic acid.

That is why the scoping review's conclusion is about prevention rather than treatment: "Prevention through adequate dilution and correct injection technique remains the most evidence-supported approach."

For a patient, this converts into a simple rule. Start conservatively. A course can always be extended; 25 months of a result you dislike cannot be shortened.

What to ask at a consultation

How many millilitres are you reconstituting each vial with? This is the single question most connected to the published nodule rates, and a clinic that does this often will answer it without hesitation.
How many sessions, at what interval, and what is the total cost? It is a course.
When should I judge the result? The answer should be months, not weeks.
What is the plan if a nodule appears at nine months? Ask before, not after.
Which product, in Korean? Several PLLA products are sold in South Korea beyond the original brand. Check the licence.

The bottom line

Sculptra builds volume through your own collagen over months and the improvement is sustained for at least 25 months — but the reviewers who found that rate the whole evidence base as low quality. Nodules are the real trade-off: reported at 1.2–14% in one review and 6–41% in another, with dilution volume the variable that separates them, and with onset sometimes past a year. Nothing dissolves it, so ask how much diluent is being used, start conservatively, and judge late.

Frequently asked questions

How long does Sculptra last?: Longer than hyaluronic acid filler. The 2024 systematic review found improvements in facial lipoatrophy sustained for at least 25 months, with increased dermal thickness. That durability is the main argument for it, and it cuts both ways — a result you dislike lasts just as long.
How likely are nodules?: This is the honest weak point, because the two reviews do not agree. A 2024 systematic review of 11 trials reports nodule rates across studies of 6% to 41%. A 2026 scoping review of 40 studies puts incidence at 1.2% to 14%, and explains the spread: early studies used low dilution volumes of 2–3 mL and had much higher rates, while 8–10 mL per vial brings it to roughly 1.3–4%.
What makes nodules more likely?: Dilution volume above all — the scoping review states that higher quantities of diluent correlate with fewer nodules, and that facial treatment typically uses about 8–10 mL per vial. Injection depth and site also matter, with the periorbital region, temples and nasolabial folds named as higher risk. This is a technique-dependent treatment.
When would a nodule appear?: Two patterns. Early, at 4 to 8 weeks, from particle aggregation. Or delayed, after six months, most commonly between 9 and 14 months, and occasionally beyond two years. So a smooth result at three months is not proof you are past it.
Can Sculptra be dissolved?: No. Hyaluronidase dissolves hyaluronic acid and has no effect on poly-L-lactic acid. The scoping review's own conclusion is that prevention through adequate dilution and correct technique is the most evidence-supported approach — because management after the fact is harder.
Sculptra or ordinary filler?: They answer different questions. Filler places volume where it is injected, works immediately, and can be dissolved. Sculptra provokes a diffuse collagen response over months, lasts far longer, and cannot be undone. For a defined hollow, filler. For general facial volume loss over a broad area, this is the category — accepting that you are committing.

Medical evidence

Systematic review2024n = 1169
Efficacy and Safety of Poly-l-Lactic Acid in Facial Aesthetics: A Systematic Review
"PLLA has been demonstrated to be a highly effective and long-lasting treatment for facial aesthetics with a reasonable safety profile. However, all findings are supported by low-quality evidence."
Systematic review2026
The Management of Poly-L-Lactic Acid (PLLA) Nodules: A Scoping Review and Evidence-Mapped Clinical Pathway
"Prevention through adequate dilution and correct injection technique remains the most evidence-supported approach." Nodule incidence 1.2–14% depending on dilution protocol, falling to roughly 1.3–4% at 8–10 mL or more per vial.

Sources

Listed in the order they are used. Source class follows the methodology.

1.Efficacy and Safety of Poly-l-Lactic Acid in Facial Aesthetics: A Systematic Review, Polymers (Basel), 2024Peer-reviewed researchaccessed 2026-09-0811 randomised controlled trials, approximately 1,169 participants. Four studies found increased dermal thickness and significant improvement in facial lipoatrophy sustained at least 25 months; PLLA superior to injectable human collagen in two studies and to polyacrylamide hydrogel in three. Adverse events mild to moderate — bruising, haematoma, tenderness, nodules, oedema — with nodule rates across studies of 6–41% and one study reporting 7% severe adverse events at two years. Five of eleven studies at high risk of bias; evidence rated low quality.
2.The Management of Poly-L-Lactic Acid (PLLA) Nodules: A Scoping Review and Evidence-Mapped Clinical Pathway, Cureus, 2026Peer-reviewed researchaccessed 2026-09-0840 studies (14 case reports, 12 case series, 6 retrospective cohorts, 2 randomised trials, 4 systematic reviews, 2 consensus opinions). Nodule incidence 1.2–14% depending on dilution; early studies at 2–3 mL dilution had much higher rates, while 8–10 mL or more per vial gives roughly 1.3–4%. Onset either early at 4–8 weeks or delayed beyond six months, most commonly 9–14 months and occasionally past 24 months. Higher-risk sites named as periorbital, temporal and nasolabial.
3.의약품안전나라 (Drug Safety Korea), Ministry of Food and Drug SafetyGovernment / public bodyaccessed 2026-09-08Where the Korean licence for an injectable is looked up under its Korean product name. Several PLLA products are sold in South Korea beyond the original brand.

Concerns it addresses

Related treatments